RDTCF (Rapid Dose Therapeutics) Revenue per Share : $0.01 (TTM As of Nov. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Rapid Dose Therapeutics Revenue per Share?

Rapid Dose Therapeutics's revenue per share for the three months ended in Nov. 2024 was $0.00. Rapid Dose Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Nov. 2024 was $0.01.

During the past 12 months, the average Revenue Per Share Growth Rate of Rapid Dose Therapeutics was 44.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Rapid Dose Therapeutics's Revenue per Share or its related term are showing as below:

During the past 13 years, Rapid Dose Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 91.30% per year. The lowest was 91.30% per year. And the median was 91.30% per year.

RDTCF's 3-Year Revenue Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 1
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Rapid Dose Therapeutics Revenue per Share Historical Data

The historical data trend for Rapid Dose Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Revenue per Share Chart

Rapid Dose Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Revenue per Share

Get a 7-Day Free Trial

0.01

Rapid Dose Therapeutics Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Revenue per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Rapid Dose Therapeutics's Revenue per Share

For the Biotechnology subindustry, Rapid Dose Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's PS Ratio falls into.

Save Embed

;

Save Embed

;

Rapid Dose Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Rapid Dose Therapeutics's Revenue Per Share for the fiscal year that ended in Feb. 2024 is calculated as

Revenue Per Share (A: Feb. 2024 )	=	Revenue (A: Feb. 2024 )	/	Shares Outstanding (Diluted Average) (A: Feb. 2024 )
	=	0.756	/	104.964
	=	0.01

Rapid Dose Therapeutics's Revenue Per Share for the quarter that ended in Nov. 2024 is calculated as

Revenue Per Share (Q: Nov. 2024 )	=	Revenue (Q: Nov. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Nov. 2024 )
	=	0.359	/	124.174
	=	0.00

Revenue per Share for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01

Rapid Dose Therapeutics (OTCPK:RDTCF) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Rapid Dose Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (OTCPK:RDTCF) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

DOSE:Canada

Address

1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4

Website

https://www.rapid-dose.com

Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.